Transmedics Group Stock

Transmedics Group Current Assets

The Current Assets of Transmedics Group (TMDX) as of Aug 4, 2026 is 553.50 M USD. In the previous year, Current Assets was 497.22 M USD — a change of 11.32% (higher).

Current Assets

553.50 MUSD

YoY

11.32%

Last updated:

Current Assets of Transmedics Group is 2026 553.50 M USD. Current Assets of Transmedics Group was 2025 497.22 M USD. It decreases by 11.32% higher compared to the previous year.
Access this data via the Eulerpool API

Transmedics Group Stock analysis

What does Transmedics Group do? Transmedics Group Inc is a company dedicated to the development and manufacturing of medical devices for organ transplantation. The company was founded in 1998 and is headquartered in Andover, Massachusetts, USA. Transmedics' business model is based on offering a unique and innovative technology for organ preservation during transport from donor to recipient. The patented Organ Care System (OCS) platform includes a range of state-of-the-art medical devices specifically designed for organ transport. Transmedics' Organ Care System includes three main devices: OCS Heart, OCS Lung, and OCS Liver. Each device is tailored for organ preparation and transport, providing individualized support based on the specific requirements of each organ and different transfer protocols. The OCS technology uses hypothermic (cold) perfusion to preserve the organ during transport. By continuously monitoring and supporting the organ's physiological functions, the OCS system can improve the survival rate of donor organs while reducing the time spent outside the body. Transmedics also offers comprehensive services, including the availability of OCS devices and qualified personnel to provide support throughout the transplantation process. Transmedics' customers include leading transplant centers and hospitals worldwide. The company works closely with these customers to ensure that its OCS devices meet the specific requirements of each transplantation program and help them achieve more successful transplantations. Transmedics' history is marked by a passion for improving transplantation medicine and saving lives through the provision of advanced technologies and solutions. The company has made significant progress in recent years and has experienced strong growth in all areas. Transmedics has also received a number of awards and recognition for its commitment to improving transplantation medicine. For example, in 2020, the company received the Red Herring Top 100 Global Award and was recognized for the seventh consecutive year as one of the fastest-growing companies by Deloitte. Overall, Transmedics is a leading provider of innovative medical devices for transplantation medicine. Through its organic technology and comprehensive service, the company supports transplant centers and hospitals worldwide in performing more successful transplantations and saving patients' lives. Transmedics Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transmedics Group stock

Current Assets of Transmedics Group is 553.50 M USD in 2026.

Current Assets of Transmedics Group changed from 497.22 M USD to 553.50 M USD, representing a 11.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Transmedics Group since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Transmedics Group historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Transmedics Group

All Key Metrics — Transmedics Group